참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Mannitol | HCID 6251 | — |
| 반응물 | L-Cysteine hydrochloride monohydrate | HCID 23462 | — |
| 반응물 | Sodium Citrate Dihydrate | HCID 71474 | — |
| 반응물 | 2-Methoxyisobutyl isonitrile | HCID 130600 | — |
| 반응물 | Sodium pertechnetate | HCID 74086836 | — |
| 생성물 | Cardiolite (TN) | HCID 5384 | — |
반응 단계
The kit includes a lyophilized mixture of a copper complex of MIBI (tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate ([Cu(MIBI)4]BF4)) as the active ingredient, sodium citrate dihydrate as a buffer, L-cysteine hydrochloride monohydrate as a stabilization aid, mannitol as a lyophilization aid, and stannous chloride dihydrate as a reducing agent. Prior to use, the lyophilized mixture is reconstituted with sodium pertechnetate (99mTc) and boiled to form technetium (99mTc) Sestamibi. The U.S. Pharmacopoeia (29th Ed.) requires that a mean of not less than 90% (corrected area percentage) of the total radioactivity is represented by 99mTc-Sestamibi, and a mean of not more than 5% (corrected area percentage) of the total radioactivity is present as 99mTc pentamibi dimethylvinyl isonitrile.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US07563920B2 |
|---|
| 출처 데이터셋 | uspto-grants-2009_07 |
|---|
| ORD ID | ord-7836256d1ac14ee49b277cc2f5533549 |
|---|
| 출처 메모 | uspto-grants-2009_07 |
|---|